External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder.

@article{Nuhn2012ExternalVO,
  title={External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder.},
  author={P Nuhn and M. May and H M Fritsche and Alexander Buchner and Sabine D Brookman-May and Christian Bolenz and Rudolf Moritz and Evelyn Herrmann and Maximillian Burger and Thomas H{\"o}fner and J{\"o}rg Ellinger and Derya Tilki and Jan Roigas and Mario Zacharias and Lutz Trojan and Christian Wuelfing and Florian May and S Melchior and Axel Haferkamp and Christian Peter Gilfrich and Markus Hohenfellner and Wolf Ferdinand Wieland and Stefan Cajetan M{\"u}ller and Christian G Stief and Patrick Jan Bastian},
  journal={European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
  year={2012},
  volume={38 7},
  pages={
          637-42
        }
}
PURPOSE To perform the first external validation of a recently identified association between disease-free survival at two years (DFS2) or three years (DFS3) and overall survival at five years (OS5) in patients after radical cystectomy (RC) for muscle-invasive urothelial carcinoma of the bladder (UCB). METHODS AND METHODS Records of 2483 patients who underwent RC for UCB at eight European centers between 1989 and 2008 were reviewed. The cohort included 1738 patients with pT2-4a tumors and… CONTINUE READING